Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets down 0.9% for the week
Fri, 18 May Closing

Indices in the Indian stock market continued their bounce back journey during the closing stages of the day and as a consequence, managed to close the day comfortably in the positive. While BSE-Sensex closed higher by around 80 points, gains on the NSE-Nifty came in at around 20 points. BSE Mid Cap and BSE Small Cap indices could not overcome the resistance and hence closed the day marginally in the negative. Nearly three stocks gained for every one that closed the day in the negative on the Sensex.

Almost all the Asian indices closed weak today with European indices too trading in the red currently. The rupee was placed Rs 54.5 to the dollar at the time of writing.

On account of today's recovery, the loss for the full week has been restricted to a shade under 1%. However, with the global financial markets poised as they are, we won't be surprised if even 15,000 on the Sensex gets taken out. This would however make the markets even more attractive from a long term perspective. Anything that comes down in price, stock markets included, deserves more buying and not less. However, due to our differently wired brains, most of us start selling just when prices are heading down. Avoiding this tendency is one of the cornerstones to successful investing we believe.

Good times seem to be finally here for the beleaguered airline sector. First, the fall in crude prices and now reports are doing the rounds that the 49% FDI in the sector, which had been held back for quite some time now could finally see the light of the day over the next few weeks. The development is likely to bring a great deal of relief to the sector on account of its debt problems in the midst of a tight liquidity situation. Most of the stocks in the sector closed positive today.

Pharma major Sun Pharma has received an approval from US FDA for its abbreviated new drug application for the generic version of Plavix, Clopidogrel tablets USP 75 mg. This assumes importance in the light of the fact that it will open up an US market of the size of US$ 6.7 bn for the firm. The approval comes close on the heels of an earlier approval for its abbreviated new drug application for generic version of Zyprexa. The stock closed marginally higher on the bourses today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets down 0.9% for the week". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.